research use only

Clozapine N-oxide (CNO) DREADD Agonist

Name: Clozapine N-oxide (CNO)
Brand: Selleck Chemicals
SKU: S6887
Availability: InStock
Rating: 5 (11 reviews)

Cat.No.S6887

CNO (Clozapine N-oxide) is a metabolite of Clozapine (GLXC-06516) and an agonist of human muscarinic designer receptors (Designer Receptors Exclusively Activated by Designer Drugs, DREADDs). Clozapine is a potent dopamine (DA) antagonist and a selective muscarinic M4 receptor agonist.Solutions are unstable and should be fresh-prepared.

Chemical Structure

Molecular Weight: 342.82

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.87%

99.87

Products Often Used Together with Clozapine N-oxide (CNO)

JHU37152

It exhibits lower in vivo DREADD potency, while JHU37152 exhibits high in vivo DREADD potency.

JHU37160

JHU37160 exhibits higher blood-brain barrier penetrance and DREADD selectivity in vivo than this compound.

DREADD agonist 21

Repeated administration of this compound and DREADD agonist 21 contributes to an unusual organization of the gut microbiota in adult mice.

Related Targets	Adrenergic Receptor 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel GluR MAO Beta Amyloid NMDAR P2 Receptor Trk receptor Serotonin Transporter Notch Cannabinoid Receptor P-gp CaMK Opioid Receptor BACE Sigma Receptor FAAH Neurokinin Receptor OX Receptor CGRP Receptor BChE Adenosine Deaminase CCK receptor MT Receptor
Related Products	PNU-120596 Benzethonium Chloride Arecoline HBr Otilonium Bromide Lycorine Hyoscyamine (-)-Huperzine A (HupA) Nitenpyram Cytisine Chelidonine PNU-282987 Methyllycaconitine citrate (MLA) NS 1738 Stephania Extract Huperzine B PNU-282987 S enantiomer free base Hodostin Batefenterol Picfeltarraenin IB Imidafenacin Dehydroevodiamine hydrochloride Lycopodiastrum casuarinoides Extract Corydaline BNC210 RHC 80267 Nodakenin Pentoxyverine Citrate Desmethylanethol trithione Acanthopanax Senticosus Extract Itopride hydrochloride

Chemical Information, Storage & Stability

Molecular Weight	342.82	Formula	C₁₈H₁₉ClN₄O	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	34233-69-7	--		Storage of Stock Solutions	Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.

Solubility

In vitro
Batch:

DMSO : 68 mg/mL (198.35 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 68 mg/mL

Ethanol : 8 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.400mg/ml (9.92mM)	Taking the 1 mL working solution as an example, add 50 μL 68 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	DREADD ^[1] Dopamine receptor ^[2] muscarinic M4 receptor ^[1]
In vitro	CNO is a synthetic small molecule actuator for muscarinic acetylcholine DREADDs.
In vivo	Clozapine N-oxide (CNO), an agonist of human muscarinic designer receptor (DREADDs), is converted to clozapine and exerts clozapine-like behavioral effects in both mice and rats further emphasizes the need for appropriate control groups in studies employing DREADDs.^[4]
References	[1] https://pubmed.ncbi.nlm.nih.gov/29497149/ [2] https://pubmed.ncbi.nlm.nih.gov/31214037/ [3] https://pubmed.ncbi.nlm.nih.gov/7895765/ [4] https://pubmed.ncbi.nlm.nih.gov/29497149/ [5] https://pubmed.ncbi.nlm.nih.gov/30038895/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00372242	Completed	Mild and Moderate Malnourished Children	International Centre for Diarrhoeal Disease Research Bangladesh	December 2000	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):